Have you been touched by a Stanford cancer clinical trial? Your story will provide courage and hope to others. We want to hear from you!
Seattle Genetics announced FDA approval for Brentuximab Vedotin (Adcetris) in combination with chemotherapy for peripheral T-cell Lymphoma, based on the ECHELON-2 (SGN35-014) study conducted in part at Stanford by the Advani team members. For more information please see the press release.
Congratulations to Jessica, Sipra, Thu and the rest of the team for their contribution to the approval of treatment for this difficult to treat disease.
The Developmental Therapeutics team is celebrating a new FDA approval based on data generated on the study LOXO-TRK-15002. More than 10% of the overall data leading to the approval of Larotrectinib (Vitrakvi) was generated by Dr. Kummar and her team at Stanford. Many thanks for their hard work on this clinical trial.
Larotrectinib is an oral agent for management of solid tumors with NTRK gene fusions, a rare oncogenic driver found in more than 25 types of cancers, from sarcomas to GI and lung cancers, from breast cancer to melanoma. It is a new alternative treatment for adults and pediatric patients with metastatic or progressive disease, including cases where tumor resection is likely to cause injury or disability. It is the first therapy approved for this type of genomic abnormality, regardless of cancer type. It is also only the second drug approved for a tissue agnostic indication (across tumor histologies).
For more information please see the FDA press release.
CCTO staff: the Stanford Cancer Institute would love to hear about your clinical trial experiences.
Have you been touched by a Stanford cancer clinical trial? Your story will provide courage and hope to others. Let us know what motivates you in your work by submitting your story here.
- Have you been inspired by a patient or by a clinical trial?
- What drives you to work in cancer clinical research?